MEMPHIS, Tenn.--(BUSINESS WIRE)--Christie Medical Holdings, Inc. today announced results from its study on the VeinViewer® Vision device's TrueView imaging. The study shows that TrueView produces a 97 percent accurate vein image, which is critical for assisting clinicians in choosing the appropriate catheter gauge, and is exclusive to VeinViewer Vision family of products.
"This study reiterates how effective VeinViewer technology really is," said Chris Schnee, general manager and vice president of sales and marketing at Christie. "The accuracy rate reinforces the basis that VeinViewer provides an image clinicians can trust to make an empowered clinical decision. The device's return on investment and increased patient satisfaction scores remain unchallenged because only VeinViewer can provide pre-, during and post-access benefits."
During testing of 252 volunteers and more than 2,000 data points, Christie measured VeinViewer's real-time digitally projected vein width accuracy against top-of-the-line ultrasound technology. The study was conducted to determine whether VeinViewer accurately displayed the width of human vein patterns as compared to ultrasound, and results show a median accuracy rate of 97 percent.
Image accuracy is especially critical to clinical decision-making in neonatology units, where the tiniest of patients are treated. A recent peer-reviewed article in the Journal of Perinatology, titled "A randomized trial of the VeinViewer versus standard technique for placement of peripherally inserted central catheters (PICCs) in neonates," stated the results found that when using VeinViewer GS series, the device led to a higher rate of successful PICC placement compared with standard techniques.
"We are motivated by TrueView's capability and the clinical outcomes cited in the peer-reviewed article in the Journal of Perinatology," said Dawn Norman, manager of clinical affairs at Christie. "We plan to continue evolving our technology to provide the best possible clinical outcomes backed by best in class clinical data. We invite any customer considering vascular imaging technology, such as VeinViewer, to join us in the drive to collect evidence-based medicine in vascular access."
VeinViewer uses harmless near-infrared light and other patented technologies to project a real-time digital image of subcutaneous vasculature and blood patterns directly onto the surface of the skin. Although designed for assistance in IV starts and blood draws, VeinViewer also is proven to be beneficial in the process of spider and varicose vein treatment. Christie's study marks the first clinical testing done on the third generation device's imaging technology since the launch of the product in 2010. Since the launch of the inaugural VeinViewer device in 2006, the technology has expanded to being sold in every major market around the globe.
To learn more about VeinViewer and to read the full study, please visit www.veinviewer.com.
About Christie Medical Holdings, Inc.
Christie Medical Holdings, Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company's market-leading product, VeinViewer®, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature in real time, directly on the surface of the skin. Christie Medical Innovations is owned by Christie Digital Systems, Inc., a global visual technologies company and a subsidiary of Ushio, Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Innovations, visit www.christiedigital.com.
Contacts
Obsidian Public Relations
Lauren Hannaford, 901-312-7769
lauren@obsidianpr.com
or
Christie Medical Holdings
Erin Shelton, 901-252-3700
erin.shelton@christiedigital.com